ACRF Blood Cancer Therapeutics Centre

In 2016, Monash University in partnership with Alfred Health received $1.2 million from the Australian Cancer Research Foundation (ACRF) to establish Australia's first dedicated blood cancer research centre.  

Funding acquired from ACRF, Alfred Health and Monash University will fund cutting edge equipment to enable researchers discover more effective therapies, track patient treatment responses more closely, and improve therapies to get better outcomes overall for patients.

Our vision is to create a high throughput drug screening facility for a range of blood cancers, including leukaemia and multiple myeloma.

The Centre aims to:

  • Screen novel drug combinations targeting blood cancers and translating promising findings into proof-of-concept clinical trails
  • Investigate why some patients relapse or develop drug resistance using cutting edge technology, including next-generation sequencing and single cell technology.

Technology

The Centre has acquired several cutting edge equipment enabled by the generous support of ACRF, Alfred Health and Monash University.

  • Illumina® next-generation sequencing platforms
  • Single cell isolation for assessing cancer cell heterogeneity
  • High throughput multiplex screening of cell suspensions
  • Affymetrix™ GeneChip™ scanner for gene expression and genetic analysis

Chief Investigators
A/Prof Andrew Wei
Prof Andrew Spencer
A/Prof David Curtis
Prof Andrew Perkins
Prof Stephen Jane

With the support of the following core services and collaborators:
Dr Nick Wong
Monash Bioinformatics Platform

and
Alfred Health Pathology

For further information on the facility contact:
Prof Andrew Perkins 
andrew.perkins@monash.edu

Bonnie Dopheide
bonnie.dopheide@monash.edu

We proudly acknowledge funding support provided from:

ACRF Logo